contraindications: Not for use in women who are pregnant or planning pregnancy; contraindicated in individuals with active prostate or breast carcinoma; avoid use where pre-existing hepatic impairment is documented. Patients with type 1 diabetes or severely impaired glycaemic control require endocrinologist supervision before initiating any anabolic protocol.
side_effects: Potential effects include HPTA suppression leading to reduced endogenous testosterone production, elevated prolactin from 19-nor metabolism (monitor with serum prolactin assay every 6 weeks), fluid retention in androgen-sensitive tissues, and acne. Metabolic side effects specific to this compound include transient hypoglycaemia if carbohydrate intake is not adjusted as insulin sensitivity improves.
monitoring: Conduct baseline bloodwork before cycle start: fasting glucose, fasting insulin, HbA1c, total testosterone, LH, FSH, prolactin, and a full lipid panel. Repeat at week 6 and week 12. Track blood pressure bi-weekly. A glucometer check every 2–4 weeks is advisable given this compound's insulin-sensitising metabolic profile.
pct: Begin PCT no earlier than 3 weeks after the final injection to allow sufficient plasma clearance of the decanoate ester. A standard PCT protocol using selective oestrogen receptor modulators (e.g., Nolvadex 40/40/20/20mg or Clomid 50/50/25/25mg over four weeks) supports HPTA recovery. Continue fasting glucose monitoring through PCT, as metabolic adaptations can persist for several weeks post-cycle.